The EU Critical Medicines Act and What It Means for the UK
Alongside its wider pharmaceutical reform, the European Union has been developing a Critical Medicines Act, aimed at protecting the supply of the medicines patients depend on most. UK pharmacy leaders have been watching closely.
The idea behind the Act
The Act is designed to reduce Europe's dependence on a small number of overseas suppliers for essential medicines, encourage manufacturing within Europe, and use joint procurement and other tools to strengthen supply.
The UK perspective
UK medicine shortages have persisted for several years. In February 2026, a House of Lords committee said shortages should be treated as a national security issue. In 2026, industry voices warned that the UK risks falling behind countries taking stronger action, and the pharmaceutical industry body ABPI suggested regulatory flexibility so that some EU packs could be supplied in the UK during shortages.
Cooperation across the Channel
In March 2026, the UK Mission to the EU hosted a roundtable on how stakeholders inside and outside Europe can make medicines supply chains more resilient. Closer cooperation could help both sides weather future shocks.
What it means for buyers
For now, the practical message is unchanged: resilience comes from diversified, well-managed supply. Acorn Pharmaceuticals works across the UK and Europe and can help pharmacies and clinics plan around a shifting regulatory landscape.
Talk to Acorn Pharmaceuticals: email gb@acornpharmaceuticals.co.uk or message us on WhatsApp.
Comments